اثرات درمانی و پروفیلاکتیک کورکومین بر مسمومیت حاد کبدی ناشی از تجویز مبندازول در سگ‌های پلیس مبارزه با مواد مخدر (نژاد ژرمن شیپرد)

نوع مقاله : مقاله پژوهشی

نویسندگان

1 دانشکده دامپزشکی تبریز

2 دانشجوی کارشناسی ارشد علوم آزمایشگاهی دامپزشکی، دانشکده دامپزشکی تهران، ایران.

چکیده

پژوهش حاضر با هدف بررسی اثرات درمانی و پروفیلاکتیک کورکومین بر مسمومیت حاد کبدی ناشی از تجویز مبندازول در سگ­های نژاد ژرمن شیپرد انجام پذیرفت. در این پژوهش 20 قلاده سگ به­طور تصادفی به 4 گروه تقسیم شدند. سگ­های گروه A روزانه 150 میلی­گرم بر کیلوگرم مبندازول همزمان با مصرف غذا، به شکل خوراکی و داخل کپسول ژلاتینی دریافت کردند. سگ­های گروه B، روزانه 500 میلی­گرم بر کیلوگرم کورکومین و 150 میلی­گرم بر کیلوگرم مبندازول همزمان با مصرف غذا، به شکل خوراکی و داخل کپسول ژلاتینی دریافت کردند. سگ­های گروه C و D نیز مشابه گروه دوم تحت تیمار قرار گرفتند؛ با این تفاوت که به ترتیب 2 و 24 ساعت پس از مصرف مبندازول، کورکومین دریافت کردند. آنزیم­های ALT، AST، ALP و LDH در همه گروه­ها اندازه­گیری شد. در سگ­های گروه A، غلظت سرمی
آنزیم­های ALT، AST،ALP و LDH به­طور معنی­داری پس از 24 ساعت افزایش یافت (05/0>P). مقادیر آنزیم­ها در گروه­های B، C و D  کاهش یافت اما تأثیر آن فقط در گروه D  معنی­دار بود و غلظت آنزیم­ها در محدودة نرمال قرار گرفت (05/0>P). نتایج این پژوهش نشان داد که کورکومین به­صورت معنی­داری، دارای اثرات درمانی در مقابل مسمومیت حاد کبدی ناشی از تجویز  مبندازول است.

کلیدواژه‌ها


عنوان مقاله [English]

Therapeutic and Prophylactic Effects of Curcumin on Acute Hepatotoxicity Induced by Mebendazole Administration in Anti-narcotic Police Dogs (German shepherd)

نویسندگان [English]

  • Navid sharookhi sabur 1
  • Ali Asghar Ghorban Nejad 2
1 Veterinary Tabriz university
2 MS student of Veterinary Laboratory Sciences, Faculty of Veterinary Medicine, Tehran, Iran.
چکیده [English]

The aim of this study was to evaluate the therapeutic and prophylactic effects of curcumin on acute hepatotoxicity induced by mebendazole administration in German Shepherd dogs. In this study, 20 dogs were randomly divided into 4 groups. Group A dogs received daily 150 mg / kg of mebendazole orally and in a gelatin capsule with food. Group B dogs received daily 500 mg / kg curcumin and 150 mg / kg mebendazole orally and in gelatin capsules with food. Dogs in groups C and D were treated similar to group 2, except that they received curcumin 2 and 24 hours after taking mebendazole, respectively. ALT, AST, ALP and LDH enzymes were measured in all groups. In group A dogs, serum concentrations of ALT, AST, ALP and LDH enzymes increased significantly after 24 hours (P <0.05). Enzyme levels decreased in groups B, C and D but their effect were significant only in group D and the concentration of enzymes was in the normal range (P <0.05). The results of this study showed that curcumin has significant therapeutic effects against acute hepatotoxicity due to mebendazole administration.

کلیدواژه‌ها [English]

  • Curcumin
  • Mebendazole
  • german shepherd
  • anti-narcotics police
  1. Cotler, S., Gustafson, J. H., & Colburn, W. A. (1984). Pharmacokinetics of diazepam and nordiazepam in the cat. Journal of pharmaceutical sciences73(3), 348-351.
  2. Epstein, J., Sanderson, I. R., & MacDonald, T. T. (2010). Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. British journal of nutrition103(11), 1545-1557.
  3. Fuller, B., Dijk, S., Butler, P., Hoang, V., & Davidson, B. (2003). Pro-inflammatory agents accumulate during donor liver cold preservation: a study on increased adhesion molecule expression and abrogation by curcumin in cultured endothelial cells. Cryobiology46(3), 284-288.
  4. Gholivand, M. B., Ahmadi, F., & Pourhossein, A. (2011). Adsorptive cathodic stripping voltammetric determination of curcumin in turmeric and human serum. Collection of Czechoslovak Chemical Communications76(3), 143-157.
  5. Hong, J., Bose, M., Ju, J., Ryu, J. H., Chen, X., Sang, S., ... & Yang, C. S. (2004). Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A 2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis25(9), 1671-1679.
  6. Hsieh, C. J. A. R. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res21(2895), e2900.
  7. Kamat, A. M., Sethi, G., & Aggarwal, B. B. (2007). Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB–regulated gene products in IFN-α–sensitive and IFN-α–resistant human bladder cancer cells. Molecular cancer therapeutics6(3), 1022-1030.
  8. Karunagaran, D., Joseph, J., & Kumar, T. R. S. (2007). Cell growth regulation. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, 245-268.
  9. Mirzaei, H., Shakeri, A., Rashidi, B., Jalili, A., Banikazemi, Z., & Sahebkar, A. (2017). Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical

 

 

 

 

 

 

 

studies. Biomedicine & Pharmacotherapy85, 102-112.

  1. Moohebati, M., Yazdandoust, S., Sahebkar, A., Mazidi, M., Sharghi-Shahri, Z., Ferns, G., & Ghayour-Mobarhan, M. (2014). Investigation of the effect of short-term supplementation with curcuminoids on circulating small dense low-density lipoprotein concentrations in obese dyslipidemic subjects: a randomized double-blind placebo-controlled cross-over trial. ARYA atherosclerosis10(5), 280.
  2. Murakami, A., & Ohigashi, H. (2007). Targeting NOX, INOS and COX‐2 in inflammatory cells: chemoprevention using food phytochemicals. International journal of cancer121(11), 2357-2363.
  3. Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2016). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomedicine & pharmacotherapy82, 578-582.
  4. Pulido-Moran, M., Moreno-Fernandez, J., Ramirez-Tortosa, C., & Ramirez-Tortosa, M. (2016). Curcumin and health. Molecules21(3), 264.
  5. Sökmen, M., & Khan, M. A. (2016). The antioxidant activity of some curcuminoids and chalcones. Inflammopharmacology24(2), 81-86.
  6. Tomita, M., Kawakami, H., Uchihara, J. N., Okudaira, T., Masuda, M., Takasu, N., ... & Mori, N. (2006). Retracted: Curcumin (diferuloylmethane) inhibits constitutive active NF‐κB, leading to suppression of cell growth of human T‐cell leukemia virus type I‐infected T‐cell lines and primary adult T‐cell leukemia cells. International journal of cancer118(3), 765-772.
  7. Trujillo, J., Molina-Jijón, E., Medina-Campos, O. N., Rodríguez-Muñoz, R., Reyes, J. L., Loredo, M. L., ... & Pedraza-Chaverri, J. (2016). Curcumin prevents cisplatin-induced decrease in the tight and adherens junctions: relation to oxidative stress. Food & function7(1), 279-293.

 

 

 

 

 

 

  1. Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007). Curcumin: the Indian solid gold. The molecular targets and therapeutic uses of curcumin in health and disease, 1-75.
  2. Ahmadi, F., Valadbeigi, S., Sajjadi, S. E., Shokoohinia, Y., Azizian, H., & Taheripak, G. (2016). Grandivittin as a natural minor groove Binder extracted from Ferulago macrocarpa to ct-DNA, experimental and in silico analysis. Chemico-biological interactions258, 89-101.
  3. Boothe, D. M. (2011). Small Animal Clinical Pharmacology and Therapeutics-E-Book. Elsevier Health Sciences.
  4. Bruck, R., Ashkenazi, M., Weiss, S., Goldiner, I., Shapiro, H., Aeed, H., ... & Pines, M. (2007). Prevention of liver cirrhosis in rats by curcumin. Liver International27(3), 373-383.
  5. Chattopadhyay, I., Biswas, K., Bandyopadhyay, U., & Banerjee, R. K. (2004). Turmeric and curcumin: Biological actions and medicinal applications. Current science, 44-53.
  6. Cotler, S., Gustafson, J. H., & Colburn, W. A. (1984). Pharmacokinetics of diazepam and nordiazepam in the cat. Journal of pharmaceutical sciences73(3), 348-351.
  7. Fu, Y., Zheng, S., Lin, J., Ryerse, J., & Chen, A. (2008). Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Molecular pharmacology73(2), 399-409.
  8. Janssen-Cilag, P. (2005). Information for health professionals. Ltd, P. O. Box 9222, Newmarket, Auckland.
  9. Kahn, C. M., & Line, S. (Eds.). (2007). The Merck/Merial Manual For Pet Health: The complete health resource for your dog, cat, horse or other pets-in everyday language. Simon and Schuster.
  10. Kayne, S.B., Jepson, M.H. (2004). Veterinary Pharmacy. Publications division of the Royal Pharmaceutical Society of Great Britain, 606p.
  11. Khan, I. A., & Abourashed, E. A. (2011). Leung's encyclopedia of common natural ingredients: used in food, drugs and cosmetics. John Wiley & Sons.

 

 

 

 

 

 

 

  1. Lappin, M. R. (2001). Feline internal medicine secrets. Elsevier Health Sciences.
  2. Lee, H. Y., Kim, S. W., Lee, G. H., Choi, M. K., Jung, H. W., Kim, Y. J., ... & Chae,
  3. H. J. (2016). Turmeric extract and its active compound, curcumin, protect against
  4. chronic CCl 4-induced liver damage by enhancing antioxidation. BMC complementary and alternative medicine16(1), 1-9.
  5. Lev-Ari, S., Starr, A., Vexler, A., Karaush, V., Loew, V., Greif, J., ... & Ben-Yosef, R. (2006). Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-
  6. Regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer research26(6B), 4423-4430.
  7. Maddison, J. E., Page, S. W., & Church, D. B. (Eds.). (2008). Small animal clinical pharmacology (Vol. 5). Elsevier Health Sciences.
  8. Maheshwari, R. K., Singh, A. K., Gaddipati, J., & Srimal, R. C. (2006). Multiple biological activities of curcumin: a short review. Life sciences78(18), 2081-2087.
  9. O'Connell, M. A., & Rushworth, S. A. (2008). Curcumin: potential for hepatic fibrosis therapy?. British journal of pharmacology153(3), 403-405.
  10. Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004). Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro. Journal of neuroscience research75(6), 742-750.
  11. Sahu, A., Kasoju, N., & Bora, U. (2008). Fluorescence study of the curcumin− casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules9(10), 2905-2912.
  12. Thapa, B. R., & Walia, A. (2007). Liver function tests and their interpretation. The Indian Journal of Pediatrics74(7), 663-671.
  13. Wilhelm, E. A., Jesse, C. R., Roman, S. S., Nogueira, C. W., & Savegnago, L. (2009). Hepatoprotective effect of 3-alkynyl

 

 

 

Selenophene on acute liver injury induced by D-galactosamine and lipopolysaccharide Experimental and molecular pathology87(1), 20-26.

  1. Yang, C., Zhang, X., Fan, H., & Liu, Y. (2009). Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain research1282, 133-141.